Treatment of myelodysplastic syndromes with 5-azacytidine.

No abstract is available for this paper.

• Publication year

  2002

• Venue

  Leukemia research : a Forum for Studies on Leukemia and Normal Hemopoiesis

• Publication date

  2002-10-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S0145-2126(02)00028-0PMID 12163049
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The evaluation of low-dose cytarabine in the treatment of myelodysplastic syndromes: A phase-III intergroup study

  2005cited by this paper
• Report of an international working group to standardize response criteria for myelodysplastic syndromes.

  2000cited by this paper
• P15INK4b gene methylation and myelodysplastic syndromes.

  1999cited by this paper
• Results of topotecan single-agent therapy in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia.

  1998cited by this paper
• Treatment of anemia in myelodysplastic syndromes with granulocyte colony-stimulating factor plus erythropoietin: results from a randomized phase II study and long-term follow-up of 71 patients.

  1998cited by this paper
• International scoring system for evaluating prognosis in myelodysplastic syndromes.

  1997cited by this paper
• Allogeneic bone marrow transplantation for 93 patients with myelodysplastic syndrome.

  1993cited by this paper
• Effects of treatment with 5-azacytidine on the in vivo and in vitro hematopoiesis in patients with myelodysplastic syndromes.

  1993cited by this paper
• Randomized study of 13-cis retinoic acid v placebo in the myelodysplastic disorders.

  1988cited by this paper
• Inhibition of DNA methyltransferase and induction of Friend erythroleukemia cell differentiation by 5-azacytidine and 5-aza-2'-deoxycytidine.

  1982cited by this paper
• Correlation between hypomethylation of DNA and expression of globin genes in Friend erythroleukemia cells.

  1977cited by this paper

• Azacitidine induced lung injury: report and contemporary discussion on diagnosis and management

  2024cites this paper
• Signal regulatory protein beta 2 is a novel positive regulator of innate anticancer immunity

  2023cites this paper
• Common Genetic Variants of Fetal Hemoglobin Modify Hematological Phenotypes in MDS/MPN/Myeloma Patients Receiving Cytotoxic Drugs

  2022cites this paper
• Targeting DNA methyltransferases in Non-small-cell lung cancer.

  2021cites this paper
• Epigenetic Modulating Chemicals Significantly Affect the Virulence and Genetic Characteristics of the Bacterial Plant Pathogen Xanthomonas campestris pv. campestris

  2021cites this paper
• Bone marrow ribonucleotide reductase mRNA levels and methylation status as prognostic factors in patients with myelodysplastic syndrome treated with 5-Azacytidine

  2021cites this paper
• The evolution of nucleoside analogue antivirals: A review for chemists and non-chemists. Part 1: Early structural modifications to the nucleoside scaffold

  2018cites this paper
• Systematic review of azacitidine regimens in myelodysplastic syndrome and acute myeloid leukemia

  2018cites this paper
• Azacitidine Use for Myeloid Neoplasms

  2018cites this paper
• RETRACTED ARTICLE: 5-Azacitidine for treating acute myelogenous leukemia

  2015cites this paper
• 5-azacytidine inhibits nonsense-mediated decay in a MYC-dependent fashion

  2014cites this paper
• Azacytidine inhibits the proliferation of human promyelocytic leukemia cells (HL60) by demethylation of MGMT, DAPK and p16 genes

  2012cites this paper
• Azacitidine

  2012cites this paper
• Azacitidine in the management of patients with myelodysplastic syndromes

  2012cites this paper
• Pulmonary involvement in patients with hematological malignancies

  2011cites this paper
• DNA hypermethylation as a chemotherapy target.

  2011cites this paper
• 5-azacitidine prolongs overall survival in patients with myelodysplastic syndrome - a systematic review and meta-analysis

  2010cites this paper
• [Epigenetic therapy in myelodysplastic syndromes (MDS). Treatment with DNA methyltransferase inhibitors].

  2010cites this paper
• Pleuropulmonary Changes Induced by Drugs in Patients with Hematologic Diseases

  2010cites this paper
• Myelodysplasia: Recent Advances

  2009cites this paper
• Methylation analysis by DNA immunoprecipitation (MeDIP).

  2009cites this paper
• Azacytidine: first therapeutic opportunity for myelodysplastic syndromes

  2009cites this paper
• Azacitidine for the treatment of myelodysplastic syndrome

  2009cites this paper
• Comparison of various criteria in predicting treatment response and prognosis of patients with myelodysplastic syndrome treated with azacitidine

  2009cites this paper
• Targeted Therapy in Myelodysplastic Syndromes

  2008cites this paper
• Hypomethylation and apoptosis in 5-azacytidine-treated myeloid cells.

  2008cites this paper
• Azacitidine‐Associated Hyperthermia and Interstitial Pneumonitis in a Patient with Myelodysplastic Syndrome

  2007cites this paper
• Recent advances in myelodysplastic syndromes.

  2007cites this paper
• Intensive chemotherapy is not recommended for patients aged >60 years who have myelodysplastic syndromes or acute myeloid leukemia with high‐risk karyotypes

  2007cites this paper
• The use of hypomethylating agents in the treatment of hematologic malignancies

  2007cites this paper
• The role of azacitidine in the treatment of myelodysplastic syndromes

  2007cites this paper
• DNA hypermethylation of myeloid cells, a novel therapeutic target in MDS and AML.

  2006cites this paper
• Novel agents for the management of myelodysplastic syndromes.

  2006cites this paper
• Epigenetische Inaktivierung von Genexpression

  2006cites this paper
• Molecularly targeted therapies in myelodysplastic syndromes and acute myeloid leukemias

  2006cites this paper
• A pharmacodynamic study of 5-azacytidine in the P39 cell line.

  2006cites this paper
• Treatment of acute myelogenous leukemia with outpatient azacitidine

  2006cites this paper
• Azacitidine; Erlotinib

  2005cites this paper
• FDA drug approval summary: azacitidine (5-azacytidine, Vidaza) for injectable suspension.

  2005cites this paper
• Myelodysplasic syndromes: a comprehensive review.

  2005cites this paper
• The silence of the genes: epigenetic disturbances in haematopoietic malignancies

  2005cites this paper
• Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies.

  2005cites this paper
• Epigenetic treatment of hematopoietic malignancies: in vivo targets of demethylating agents.

  2005cites this paper
• Advances in myelodysplastic syndrome: nursing implications of azacitidine.

  2005cites this paper
• Azacitidine‐Induced Interstitial and Alveolar Fibrosis in a Patient with Myelodysplastic Syndrome

  2005cites this paper
• Approval Summary: Azacitidine for Treatment of Myelodysplastic Syndrome Subtypes

  2005cites this paper
• Treatment of pediatric myelodysplastic syndromes and juvenile myelomonocytic leukemia: the Brazilian experience in the past decade.

  2004cites this paper
• Nouvelles formes de la 5-azacytidine

  2004cites this paper
• DNA Demethylating Agents: Clinical Uses

  2004cites this paper
• Modulation of angiogenesis in patients with myelodysplastic syndrome.

  2004cites this paper
• Formes de la 5-azacytidine

  2004cites this paper
• DNA methyltransferase inhibitors in myelodysplastic syndrome.

  2004cites this paper
• Recent progress in the treatment of myelodysplastic syndrome in adult patients

  2003cites this paper